Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
J Immunother Cancer
; 10(6)2022 06.
Article
in En
| MEDLINE
| ID: mdl-35728875
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Biomarkers, Tumor
/
Melanoma
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
J Immunother Cancer
Year:
2022
Type:
Article
Affiliation country:
United States